The healthcare burden imposed by liver disease in aging baby boomers

Current Gastroenterology Reports

Volumn 12, Issue 1, 2010, Pages 1-6

  Davis, Gary L ^a   Roberts, William L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alcoholic liver disease; Fatty liver disease; Hepatitis C; Hepatocellular carcinoma

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B VACCINE; INTERFERON;

AGING; ALCOHOL LIVER DISEASE; BABY BOOMER; BARIATRIC SURGERY; CAUSE OF DEATH; CHRONIC LIVER DISEASE; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; FATTY LIVER; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS C; HUMAN; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MATHEMATICAL MODEL; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; REVIEW; TREND STUDY; UNITED STATES;

AGED; AGED, 80 AND OVER; AGING; CARCINOMA, HEPATOCELLULAR; FORECASTING; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; POPULATION DYNAMICS; UNITED STATES;

EID: 74849128654     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0087-2     Document Type: Review

References (52)

1. US Department of Health and Human Services: Health, United States, 2008. Available at http://www.cdc.gov/nchs/data/hus/hus08.pdf#026. Accessed October 2009.
2. C Hernandez M Jansa M Vidal, et al. 2009 The burden of chronic disorders on hospital admissions prompts the need for new modalities of care: a cross-sectional analysis in a tertiary hospital QJM 102 193 202 10.1093/qjmed/hcn172 1:STN:280:DC%2BD1M7kslGmuw%3D%3D 19147657
3. Centers for Disease Control and Prevention: Chronic disease overview. Available at http://www.cdc.gov/nccdphp/overview.htm. Accessed October 2009.
4. Calkins E, Boult C, Wagner E, et al.: New Ways to Care for Older People: Building Systems Based on Evidence. New York: Springer; 1999.
5. C Boult M Altmann D Gilbertson, et al. 1996 Decreasing disability in the 21st century: the future effects of controlling six fatal and nonfatal conditions Am J Public Health 86 10 1388 1393 10.2105/AJPH.86.10.1388 1:STN:280:DyaK2s%2FjtVGltw%3D%3D 8876506
6. WR Kim RS Brown Jr NA Terrault H El-Serag 2002 Burden of liver disease in the United States: summary of a workshop Hepatology 36 227 242 10.1053/jhep.2002.34734 12085369 (Pubitemid 34700782)
7. BP Bell MM Manos A Zaman, et al. 2008 The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance Am J Gastroenterol 103 2727 2736 10.1111/j.1572-0241.2008.02071.x 18684170
8. Alcohol-attributable deaths and years of potential life lost-United States, 2001. MMWR Morb Mortal Wkly Rep 2004, 53:866-870.
9. T Norström M Ramstedt 2005 Mortality and population drinking: a review of the literature Drug Alcohol Rev 24 537 547 10.1080/09595230500293845 16361210 (Pubitemid 43000460)
10. Yon YH, Yi HY: Liver cirrhosis mortality in the United States. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Surveillance report 83. Available at http://pubs.niaaa.nih.gov/publications/surveillance83/Cirr05.htm. Accessed October 2009.
11. Lakins NE, LaVellee R, Williams GD, Yi HY: Apparent per capita alcohol consumption: national, state and regional trends 1977-2006. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Surveillance report 85. Available at http://pubs.niaaa.nih.gov/publications/surveillance85/CONS06.htm. Accessed October 2009.
12. Chen CM, Yi HY: Trends in alcohol-related morbidity among short-stay community hospital discharges, United States, 1979-2006. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Surveillance report 84. Available at: http://pubs.niaaa.nih.gov/publications/surveillance.htm. Accessed October 2009.
13. KE Norberg LJ Bierut RA Grucza 2009 Long-term effects of minimum drinking age laws on past-year alcohol and drug use disorders Alcohol Clin Exp Res 33 2180 2190 10.1111/j.1530-0277.2009.01056.x 19775322
14. AC Wagenaar MJ Salois KA Komro 2009 Effects of beverage alcohol price and tax levels on drinking: a meta-analysis of 1003 estimates from 112 studies Addiction 104 179 190 10.1111/j.1360-0443.2008.02438.x 19149811
15. LI Soberg MV Maciosek NM Edwards 2008 Primary care intervention to reduce alcohol misuse ranking its health impact and cost effectiveness Am J Prev Med 34 143 152 10.1016/j.amepre.2007.09.035
16. GL Armstrong MJ Alter GM McQuillan HS Margolis 2000 The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States Hepatology 31 777 782 10.1002/hep.510310332 1:STN:280:DC%2BD3c7nt1SgsQ%3D%3D 10706572
17. GL Davis JE Albright SF Cook DM Rosenberg 2003 Projecting future complications of chronic hepatitis C in the United States Liver Transpl 9 331 338 10.1053/jlts.2003.50073 12682882 (Pubitemid 36443043)
18. GL Armstrong A Wasley EP Simard, et al. 2006 The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 705 714 16702586
19. JE Everhart CE Ruhl 2009 Burden of digestive disease in the United States part III: liver, biliary tract and pancreas Gastroenterology 136 1134 1144 10.1053/j.gastro.2009.02.038 19245868 This review examines the trends in healthcare utilization for common liver diseases in recent years. Although it provides excellent details of viral hepatitis trends, it does not address the growth of fatty liver disease in the population
20. T Poynard P Bedossa P Opolon 1997 Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 825 832 10.1016/S0140-6736(96)07642-8 1:STN:280:DyaK2s3js1ymug%3D%3D 9121257 (Pubitemid 27129209)
21. M Yano H Kumada M Kage, et al. 1996 The long-term pathological evolution of chronic hepatitis C Hepatology 23 1334 1340 10.1002/hep.510230607 1:STN:280:DyaK283ktlWmsg%3D%3D 8675148
22. T Poynard V Ratziu F Charlotte, et al. 2001 Rates and risk factors of liver fibrosis progression in persons with chronic hepatitis C J Hepatology 34 730 739 10.1016/S0168-8278(00)00097-0 1:STN:280:DC%2BD38%2FhsleitQ%3D%3D (Pubitemid 32488789)
23. P Pradat N Voirin HL Tillmann, et al. 2007 Progression to cirrhosis in hepatitis C patients: an age-dependent process Liver Int 27 335 339 10.1111/j.1478-3231.2006.01430.x 17355454 (Pubitemid 46416623)
24. M Wright R Goldin A Fabre, et al. 2003 Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study Gut 52 574 579 10.1136/gut.52.4.574 1:STN:280:DC%2BD3s7hvVansg%3D%3D 12631672 (Pubitemid 36363414)
25. G Fattovich G Giustina F Degos, et al. 1997 Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 persons Gastroenterology 112 463 472 10.1053/gast.1997.v112.pm9024300 1:STN:280:DyaK2s7ns1Olsw%3D%3D 9024300 (Pubitemid 27078833)
26. A Sangiovanni GM Prati P Fasani, et al. 2006 The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 persons Hepatology 43 1303 1310 10.1002/hep.21176 16729298 (Pubitemid 43980109)
27. H El-Serag 2004 Hepatocellular carcinoma: recent trends in the United States Gastroenterology 127 S27 S34 10.1053/j.gastro.2004.09.013 15508094 (Pubitemid 39423367)
28. AM DiBisceglie AC Lyra M Schwartz, et al. 2003 Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status Am J Gastroenterol 98 2060 2063 10.1016/S0002-9270(03)00552-5
29. N Snowberger S Chinnakotla RM Lepe, et al. 2007 Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis Aliment Pharmacol Ther 26 1187 1194 1:STN:280:DC%2BD2snitVKhug%3D%3D 17944733
30. F Degos C Christidis N Ganne-Carrie, et al. 2000 Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death Gut 47 131 136 10.1136/gut.47.1.131 1:STN:280:DC%2BD3czitVOqtw%3D%3D 10861275 (Pubitemid 30430422)
31. SF Altekruse KA McGlynn ME Reichman 2009 Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 1485 1491 10.1200/JCO.2008.20.7753 19224838 The most recent report from the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database on the rapidly rising incidence of HCC in the United States
32. MW Fried ML Shiffman R Reddy, et al. 2002 Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 10.1056/NEJMoa020047 1:CAS:528:DC%2BD38Xnt12rtb0%3D 12324553
33. JM Pawlotsky S Chevaliez JG McHutchison 2007 The hepatitis C virus life cycle as a target for new antiviral therapies Gastroenterology 132 1979 1998 10.1053/j.gastro.2007.03.116 1:CAS:528:DC%2BD2sXmsVymsbw%3D 17484890 (Pubitemid 46695724)
34. C Cammà D Di Bona F Schepis, et al. 2004 Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data Hepatology 39 333 342 10.1002/hep.20073 14767986 (Pubitemid 38222174)
35. S Bruno PM Battezzati G Bellati, et al. 2001 Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C J Hepatol 34 748 755 10.1016/S0168-8278(01)00062-9 1:CAS:528:DC%2BD3MXkvVKrsrg%3D 11434622 (Pubitemid 32488791)
36. BJ Veldt EJ Heathcote H Wedemeyer, et al. 2007 Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 677 684 18025443 This paper by Veldt et al. (and the previous reference by Bruno et al.) document the long-term beneficial effects of successful antiviral treatment on the occurrence of liver failure and HCC incidence among cirrhotic patients with chronic hepatitis C
37. Centers for Disease Control and Prevention: Hepatitis B FAQs for healthcare professionals. Available at http://www.cdc.gov/hepatitis/HBV/HBVfaq. htm#overview. Accessed October 2009.
38. WD Carey 2009 The prevalence and natural history of hepatitis B in the 21st century Cleve Clin J Med 76 Suppl S2 S5 10.3949/ccjm.76.s3.01 19465705
39. S Parikh D Hyman 2007 Hepatocellular cancer: a guide for the internist Am J Med 120 194 202 10.1016/j.amjmed.2006.11.020 17349437 (Pubitemid 46341174)
40. Y Barazani JR Hiatt MJ Tong, et al. 2007 Chronic viral hepatitis and hepatocellular carcinoma World J Surg 31 1243 1248 10.1007/s00268-007-9041-3 17440771 (Pubitemid 47029929)
41. WR Kim NA Terrault RA Pedersen, et al. 2009 Trends in waiting list registration for liver transplantation for viral hepatitis in the United States Gastroenterology 137 1680 1686 10.1053/j.gastro.2009.07.047 19632234
42. JL Dienstag 2009 Benefits and risks of nucleoside analog therapy for hepatitis B Hepatology 49 5 Suppl S112 S121 1:CAS:528:DC%2BD1MXlvFKqsLs%3D 19399795
43. JG O'Leary H Randall N Onaca, et al. 2009 Post-liver transplant survival in hepatitis C patients is improving over time Liver Transpl 15 360 368 10.1002/lt.21691 19326409
44. AH Mokdad BA Bowman ES Ford, et al. 2001 The continuing epidemics of obesity and diabetes in the United States JAMA 286 1195 1200 10.1001/jama.286.10.1195 1:STN:280:DC%2BD3MrhvVegsw%3D%3D 11559264
45. Centers for Disease Control and Prevention: Overweight and obesity: data and statistics. Available at http://www.cdc.gov/obesity/data/index.html. Accessed October 2009.
46. S Al Snih KJ Ottenbacher KS Markides, et al. 2007 The effect of obesity on disability vs mortality in older Americans Arch Intern Med 167 774 780 10.1001/archinte.167.8.774 17452539 (Pubitemid 46658334)
47. CG Solomon JE Manson 1997 Obesity and mortality: a review of the epidemiologic data Am J Clin Nutr 66 1044S 1050S 1:CAS:528:DyaK2sXmsFeku7o%3D 9322585
48. LA Adams JF Lymp J St Sauver, et al. 2005 The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 113 121 10.1053/j.gastro.2005.04.014 16012941 Combined with the data from the Centers for Disease Control and Prevention on obesity trends in the United States, this paper looking at progression and causes of death among patients with fatty liver disease is sobering (Pubitemid 41002048)
49. K Kloor 2009 Prosperity plague Science 325 256 257 10.1126/science.325- 254
50. VK Rustgi GL Davis SK Herrine, et al. 2008 Future trends in hepatology: challenges and opportunities Hepatology 48 655 661 10.1002/hep.22451 18666245
51. C Koebnick D Getahun K Reynolds, et al. 2009 Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults J Pediatr Gastroenterol Nutr 48 597 603 10.1097/MPG.0b013e318192d224 19412009
52. MK Robinson 2009 Surgical treatment of obesity-weighing the facts New Engl J Med 361 520 521 10.1056/NEJMe0904837 1:CAS:528:DC%2BD1MXpt1Crsbo%3D 19641209